Skip to main content

LCD L39479: MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma

LCD L39479, MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma, is the Local Coverage Determination that Wisconsin Physicians Service Insurance Corporation applies to claims from 48 states (AK, AL, AR, AZ, CA, CO, CT, DE and others), effective 2025-05-01 and first in force 2023-08-13. The policy text runs 253 words, and its billing and coding article A59261 lists 18 ICD-10-CM codes that support medical necessity for 3 procedure codes. 3 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 18 covered ICD-10-CM codes: the same total as L39345 (Palmetto GBA, 18 codes, revised 2023-08-06) and the same total as L39373 (Noridian Healthcare Solutions, LLC, 18 codes, revised 2026-01-22).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Wisconsin Physicians Service Insurance Corporation
States and territories
48
AK AL AR AZ CA CO CT DE FL GA HI IA ID IL IN KS KY LA MA MD ME MI MO MS MT NC ND NE NH NJ NM NV OH OK OR PA RI SC SD TN TX UT VA VT WA WI WV WY
Revision effective
2025-05-01
Original effective
2023-08-13
Policy text
253 words
Covered ICD-10 codes (articles)
18

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L39479
ContractContractorTypeStates
05101Wisconsin Physicians Service Insurance CorporationMAC - Part AIA
05201Wisconsin Physicians Service Insurance CorporationMAC - Part AKS
05301Wisconsin Physicians Service Insurance CorporationMAC - Part AMO
05401Wisconsin Physicians Service Insurance CorporationMAC - Part ANE
05102Wisconsin Physicians Service Insurance CorporationMAC - Part BIA
05202Wisconsin Physicians Service Insurance CorporationMAC - Part BKS
05302Wisconsin Physicians Service Insurance CorporationMAC - Part BMO
05402Wisconsin Physicians Service Insurance CorporationMAC - Part BNE
08101Wisconsin Physicians Service Insurance CorporationMAC - Part AIN
08102Wisconsin Physicians Service Insurance CorporationMAC - Part BIN
08201Wisconsin Physicians Service Insurance CorporationMAC - Part AMI
08202Wisconsin Physicians Service Insurance CorporationMAC - Part BMI
05901Wisconsin Physicians Service Insurance CorporationMAC - Part AAK AL AR AZ CA CO CT DE FL GA HI IA ID IL IN KS KY LA MA MD ME MI MO MS MT NC ND NE NH NJ NM NV OH OK OR PA RI SC SD TN TX UT VA VT WA WI WV WY

Billing and coding article A59261: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A59261 (Billing and Coding: MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A59261: Billing and Coding: MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma (Billing and Coding, effective 2025-09-25)

Covered ICD-10-CM codes
18
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
3
Full article
cms.gov record
First 18 covered ICD-10-CM codes in A59261
ICD-10-CMDescription (FY2027)
D22.0Melanocytic nevi of lip
D22.10Melanocytic nevi of unspecified eyelid, including canthus
D22.111Melanocytic nevi of right upper eyelid, including canthus
D22.112Melanocytic nevi of right lower eyelid, including canthus
D22.121Melanocytic nevi of left upper eyelid, including canthus
D22.122Melanocytic nevi of left lower eyelid, including canthus
D22.20Melanocytic nevi of unspecified ear and external auricular canal
D22.21Melanocytic nevi of right ear and external auricular canal
D22.22Melanocytic nevi of left ear and external auricular canal
D22.39Melanocytic nevi of other parts of face
D22.4Melanocytic nevi of scalp and neck
D22.5Melanocytic nevi of trunk
D22.61Melanocytic nevi of right upper limb, including shoulder
D22.62Melanocytic nevi of left upper limb, including shoulder
D22.71Melanocytic nevi of right lower limb, including hip
D22.72Melanocytic nevi of left lower limb, including hip
D22.9Melanocytic nevi, unspecified
D48.5Neoplasm of uncertain behavior of skin

Procedure codes: 0090U, 0314U, 81479.

Coverage indications, limitations and medical necessity

The purpose of this test is to assist dermatopathologists to arrive at the correct diagnosis of melanoma versus non-melanoma when examining skin biopsies.

This Medicare contractor will provide limited coverage for molecular Deoxyribonucleic acid (DNA)/Ribonucleic acid (RNA) assays that aid in the diagnosis or exclusion of melanoma from a biopsy when ALL of the following clinical conditions are met:

• The test is ordered by a board-certified or board-eligible dermatopathologist

• The specimen is a primary (non-metastatic, non-re-excision specimen) cutaneous melanocytic neoplasm for which the diagnosis is equivocal/uncertain (i.e., clear distinction between benign or malignant cannot be achieved using clinical and/or histopathological features alone) despite the performance of standard-of-care test procedures and relevant ancillary tests (i.e., immunohistochemical stains)

• The specimen includes an area representative of the lesion or portion of the lesion that is suspicious for malignancy

• The patient may be subjected to additional intervention, such as re-excision and/or sentinel lymph node biopsy, as a result of the diagnostic uncertainty

• The patient has not been tested with the same or similar assay for the same clinical lesion

• The test is validated for use in the intended-use population and is performed according to its stated intended-use

• The test demonstrates Analytical and Clinical Validity (AV and CV) and Clinical Utility (CU) and undergoes a technical assessment (TA) by MolDX ® to demonstrate compliance of the service with this policy

Tests that demonstrate similar indicated uses and equivalent or superior performance to covered tests may similarly be covered under this policy.

Summary of evidence (opening)

Melanoma is an aggressive cancer with an estimated 106,110 cases and 7,180 deaths in 2021. 1 The lifetime risk of developing melanoma in the United States is approximately 2.6% (1 in 38) for Caucasians, 0.1% (1 in 1,000) for African Americans, and 0.6% (1 in 167) for Latinos. 1 Melanoma is more common in men overall, but before age 50 the rates are higher in women than in men. The average age of people diagnosed with melanoma is 65. Many melanomas are curable if detected early and diagnosed accurately. The 5-year survival for localized melanoma is 99%, compared with only 27% among patients with distant metastases. 2

Melanoma can be difficult to diagnose, particularly in its earliest stages, yet accurate diagnosis of melanocytic neoplasms is vital to optimal patient outcomes. Histopathologic examination has long been the gold standard for melanoma diagnosis, and while it is adequate for most cases, evidence suggests that approximately 15-20% of all biopsied melanocytic neoplasms are difficult to diagnose by histopathology alone. 3-5 Subspecialty training and experience in dermatopathology is associated with improved diagnostic accuracy and subsequent clinical management of patients with challenging melanocytic lesions. 5-8 However, even experienced dermatopathologists disagree in some cases, and, depending on the type of lesions evaluated, diagnostic discordance may be substantial. 6,7,9,10 In equivocal cases, patients may receive diagnoses that are indeterminate or inaccurate, leading to inappropriate treatment. Unnecessary re-excisions, sentinel lymph node biopsies, and protracted clinical follow-up may result when a diagnostically challenging benign lesion is reported as indeterminate. 11,12 Conversely, a diagnostically challenging melanoma mistakenly classified as a benign nevus may result in undertreatment and subsequent progression to late-stage melanoma. 11,12 Consequently, adjuncts to histopathology have been sought in efforts to improve diagnostic accuracy in equivocal cases.

Gene expression profiles (GEP) can serve as beneficial adjuncts to histopathology in the evaluation of equivocal melanocytic lesions. The myPath ® Melanoma assay (Castle Biosciences, Phoenix, AZ) is a 23-gene expression profile (23-GEP) developed to provide an objective, reproducible, and accurate adjunctive method for differentiating malignant melanoma from benign nevi. 13-16 The test is intended for use by dermatopathologists confronting primary cutaneous melanocytic neoplasms for which the diagnosis of malignant melanoma versus benign nevus is equivocal/uncertain (i.e., a clear distinction between benign or malignant cannot be achieved using clinical and/or histopathological features alone). Use of the test in these cases increases definitive diagnoses, and evidence suggests it may reduce unnecessary procedures in benign lesions. 17,18

The myPath ® Melanoma test quantifies the expression of 23 genes by quantitative reverse transcription-polymerase chain reaction (RT-PCR). Fourteen of the 23 genes are known to be over-expressed by malignant melanomas relative to benign nevi. The remaining 9 are stably expressed reference genes which allow correction for sample-to-sample variations in RT-PCR efficiency and errors in sample quantification (normalization). The signature genes represent 3 distinct pathways that contribute to melanoma pathogenesis, including aspects of melanocyte differentiation as well as characteristics of the tumor microenvironment such as cell-cell signaling and tumor-induced host immune responses. 13,14 The test uses 5 to 7 standard-thickness (4-5 µm) sections taken from the routinely processed formalin-fixed paraffin-embedded (FFPE) tissue of the existing biopsy specimen, allowing its integration into routine clinical practice and its use even in small, early-stage lesions. The quantified expression of all 23 genes is combined algorithmically and reported as a single numerical score. That number (the myPath ® Melanoma ‘score’) is plotted on a scale that depicts the entire range of scores observed in clinical validation studies. 14 Physicians receive a report showing this single numerical score and the corresponding classification: ‘likely malignant’, ‘likely benign’, or ‘indeterminate’.

The contractor cites 36 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2023-08-13
Current revision effective
2025-05-01
Last reviewed by the contractor
2025-03-21
MCD version
5

Other related documents: A59455 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Wisconsin Physicians Service Insurance Corporation hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L39479 cover?

This Medicare contractor will provide limited coverage for molecular Deoxyribonucleic acid (DNA)/Ribonucleic acid (RNA) assays that aid in the diagnosis or exclusion of melanoma from a biopsy when ALL of the following clinical conditions are met: The full 253-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L39479 apply to?

Wisconsin Physicians Service Insurance Corporation applies it to Medicare claims in 48 states: AK, AL, AR, AZ, CA, CO, CT, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY. It binds only that contractor; 3 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L39479?

The companion billing and coding article A59261 lists 18 ICD-10-CM codes in 1 group that support medical necessity; the first 18 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L39479?

A denial under LCD L39479 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A59261's 18 covered diagnosis codes, then file a redetermination with Wisconsin Physicians Service Insurance Corporation within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.